慢性蕁麻疹に対するベシル酸ベポタスチン(タリオン^【○!R】錠)の臨床的有用性の検討 [in Japanese] Efficacy and Safety of Bepotastine Besilate in the Treatment of Chronic Urticaria [in Japanese]
Access this Article
Search this Article
The efficacy and safety of bepotastine besilate (Talion<SUP>®</SUP>) in the treatment of chronic urticaria were evaluated in 88 adult patients with chronic urticaria. Patients were openly treated with 20 mg/day oral bepotastine besilate for 14 days. Clinical evaluations were performed every 7 days, and patients were asked to keep a diary, recording their pruritus scores. Symptoms improved in 77.1% of the patients after two weeks and pruritus scores were reduced significantly within 24 h after oral administration in 69.6% of patients. It appears that bepotastine besilate can be ranked as a drug of first choice for the treatment of chronic urticaria, because it rapidly relieved itch and the incidence of drowsiness was relatively low.
- The Nishinihon Jourrnal of Dermatology
The Nishinihon Jourrnal of Dermatology 68(1), 69-75, 2006-02-01
Western Division of Japanese Dermatological Association